The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Journal of Surgical Oncology · 14.11.2026
DOI: 10.1002/jso.70454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 14.11.2026. Verfasst von Khalid Al Hinai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oman Medical Specialty Board, Muscat, Sultanate of Oman. Die Arbeit nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with colorectal peritoneal metastases. However, outcomes remain heterogeneous, and tumor molecular biology may influence prognosis.
Methods
We retrospectively reviewed patients with colorectal cancer and peritoneal metastases treated with CRS and HIPEC at Royal Hospital between May 2013 and August 2024. Patients were grouped by presence of genetic mutations (GM) versus no mutations (no‐GM). Primary outcomes were overall survival (OS) and recurrence‐free survival (RFS). Secondary outcomes included morbidity and prognostic factors for recurrence.
Results
Among 159 patients, 73 (45.9%) had a documented genetic mutation. Genetic mutation was associated with a shorter median RFS (8 months in the GM group vs. 27 months in the no‐GM group; p < 0.001), with 5‐year RFS of 6.0% and 45.3%, respectively. Genetic mutation was also associated with a shorter median OS on univariable analysis (37 months vs. not reached; p = 0.001). On multivariable analysis, genetic mutation status (HR 3.821, 95% CI 2.270–6.432; p < 0.001), PCI > 15 (HR 1.073; p = 0.005), and pre‐HIPEC chemotherapy (HR 2.194; p = 0.003) were independently associated with recurrence. For OS, PCI (HR 1.066; p = 0.037) and poorly differentiated tumor grade (HR 2.946; p = 0.045) were independently associated with survival, whereas genetic mutation status was not (HR 1.477; p = 0.197).
Conclusion
Genetic mutation was associated with shorter RFS after CRS and HIPEC, and this association persisted after multivariable adjustment. The association with OS was not independent of PCI and tumor grade, suggesting that disease burden may be the main driver of survival. Molecular status may complement established clinicopathological factors in patient assessment; larger prospective studies stratified by mutation type are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oman Medical Specialty Board, Muscat, Sultanate of Oman.
- General Surgery Department, Royal Hospital, Muscat, Sultanate of Oman.
- Royal Hospital, Muscat, Sultanate of Oman.
ORCID-Profile: Khalid Al Hinai, Sara Al Jahwari, Manar Nassr
Zitieren
APA
Hinai, K. A., Jahwari, S. A., & Nassr, M. (2026). The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70454
Vancouver
Hinai KA, Jahwari SA, Nassr M. The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70454
BibTeX
@article{Hinai2026,
author = {Hinai, Khalid Al and Jahwari, Sara Al and Nassr, Manar},
title = {The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70454}
}
EUVIMED